Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Employment agrmnt
Quarterly results
|
|
ADMA BIOLOGICS, INC. (ADMA)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 08/09/2023 |
8-K
| Quarterly results |
| 05/10/2023 |
8-K
| Quarterly results |
| 03/23/2023 |
8-K
| Quarterly results |
| 11/09/2022 |
8-K
| Quarterly results |
| 08/10/2022 |
8-K
| Quarterly results |
| 05/11/2022 |
8-K
| Quarterly results |
| 03/24/2022 |
8-K
| Quarterly results|
Docs:
|
"RAMSEY, N.J. and BOCA RATON, Fla., March 24, 2022 -- ADMA Biologics, Inc. , an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, today announced its fourth quarter and full year 2021 financial results. Additionally, ADMA today announced the closing of a debt refinancing with Hayfin Capital Management of $150 million, and up to an additional $25 million tied to the achievement of certain revenue targets during 2022. The first tranche of the newly issued loan from Hayfin was fully drawn and used to completely repay the obligations under the Perceptive Advisors senior secured notes, including all associated prepayment fees." |
|
| 11/10/2021 |
8-K
| Quarterly results|
Docs:
|
"RAMSEY, NJ and BOCA RATON, FL – November 10, 2021 – ADMA Biologics, Inc. , an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, today reported financial results for the three months ended September 30, 2021, its fiscal third quarter, and provided an overview of recent progress and accomplishments. “Achieving a positive gross profit and 101% year-over-year revenue growth represents a key inflection point for the Company as we continue our ongoing commercial and production ramp up. These financial milestones and accomplishments would not have been possible without the dedication and focus of ADMA’s staff, leadership and advisors. We commend the entire team for their extraordinary efforts focused on improvi..." |
|
| 08/11/2021 |
8-K
| Quarterly results |
| 03/25/2021 |
8-K
| Quarterly results |
| 11/05/2020 |
8-K
| Quarterly results|
Docs:
|
"ADMA BIOLOGICS, INC. AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF OPERATIONS Three Months Ended September 30, Nine Months Ended September 30, 2020 2019 2020 2019 REVENUES: Product revenue $ 10,240,650 $ 7,186,795 $ 28,156,571 $ 17,204,909 License revenue 35,708 35,708 107,125 107,125 Total Revenues 10,276,358 7,222,503 28,263,696 17,312,034 OPERATING EXPENSES: Cost of product revenue 11,855,464 7,916,220 42,180,319 27,812,635 Research and development 1,708,391 491,404 4,893,549 1,879,025 Plasma center operating expenses 1,218,898 456,899 2,597,444 1,705,498 Amortization of intangible assets 178,838 211,235 536,514 633,704 Selling, general and administrative 9,115,744 7,197,173 25,750,458 18,878,690 Total operating expenses 24,077,335 16,272,931 75,958,284 50,909,552 LOSS FROM OPERATIONS O..." |
|
| 05/06/2020 |
8-K
| Quarterly results |
| 03/12/2020 |
8-K
| Quarterly results|
Docs:
|
"ADMA BIOLOGICS, INC. AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF OPERATIONS Three Months Ended December 31, Year ended December 31, 2019 2018 2019 2018 REVENUES: Product revenue $ 12,001,340 $ 4,020,715 $ 29,206,249 $ 16,842,456 License revenue 35,709 35,709 142,834 142,834 Total Revenues 12,037,049 4,056,424 29,349,083 16,985,290 OPERATING EXPENSES: Cost of product revenue 11,691,603 11,142,116 39,504,238 42,194,635 Research and development 464,823 917,304 2,343,848 3,926,120 Plasma center operating expenses 464,131 2,260,379 2,169,629 7,805,619 Amortization of intangible assets 211,234 211,234 844,938 844,938 Selling, general and administrative 7,032,067 6,073,051 25,910,757 22,502,922 Total operating expenses 19,863,858 20,604,084 70,773,410 77,274,234 LOSS FROM OPERATIONS OTHER INCOM..." |
|
| 11/06/2019 |
8-K
| Quarterly results |
| 08/08/2019 |
8-K
| Quarterly results|
Docs:
|
"ADMA Biologics Reports Second Quarter and First Half 2019 Financial Results RAMSEY, N.J. and BOCA RATON, FL., – August 8, 2019 – ADMA Biologics, Inc. , a vertically integrated commercial biopharmaceutical and specialty immunoglobulin company that manufactures, markets and develops specialty plasma-derived biologics for the treatment of immune deficiencies and the prevention of certain infectious diseases, today announced its financial results for the second quarter and six months ended June 30, 2019, and provided an update on its recent achievements, operations and upcoming milestones. “We are pleased with our significant accomplishments reported during the second quarter of 2019, which include two United States Food and Drug Administration approvals, BIVIGAM® and ASCENIV™, as well a..." |
|
| 05/08/2019 |
8-K
| Quarterly results|
Docs:
|
"ADMA Biologics Reports First Quarter 2019 Financial Results RAMSEY, N.J. and BOCA RATON, FL., – May 8, 2019 – ADMA Biologics, Inc. , a vertically integrated commercial biopharmaceutical and specialty immunoglobulin company that manufactures, markets and develops specialty plasma-derived biologics for the treatment of immune deficiencies and the prevention of certain infectious diseases, today announced its financial results for the first quarter ended March 31, 2019, and provided an update on its recent achievements, operations and upcoming milestones. “We had a strong and productive start to 2019, most notably due to the United States Food and Drug Administration approval of ASCENIV™, the announcement of our fifth patent, which expands our proprietary hyperimmune immunotechnology pr..." |
|
| 03/13/2019 |
8-K
| Quarterly results|
Docs:
|
"ADMA Biologics Reports Full Year 2018 Financial Results RAMSEY, N.J. and BOCA RATON, FL., – March 13, 2019 – ADMA Biologics, Inc. , a vertically integrated commercial biopharmaceutical and specialty immunoglobulin company that manufactures, markets and develops specialty plasma-derived biologics for the treatment of immune deficiencies and the prevention and treatment of certain infectious diseases, today announced its financial results for the year ended December 31, 2018, and provided an update on its operations and upcoming milestones. “During 2018, we achieved several key objectives, most notably the improvement of our Boca Raton, FL manufacturing facility’ s FDA compliance status to Voluntary Action Indicated . This improved VAI classification has afforded us the opportunity to submit..." |
|
| 11/08/2018 |
8-K
| Quarterly results|
Docs:
|
"ADMA Biologics Reports Third Quarter 2018 Financial Results RAMSEY, N.J. and BOCA RATON, FL., – November 8, 2018 – ADMA Biologics, Inc. , a vertically integrated commercial biopharmaceutical company that develops, manufactures and markets specialty plasma-based biologics for the treatment of Primary Immune Deficiency Disease and the prevention and treatment of certain infectious diseases, today announced its financial results for the quarter and nine months ended September 30, 2018 and provided an update on its operations and upcoming milestones. “We have made substantial progress executing on our key initiatives throughout 2018. Most importantly, we improved the U.S. Food and Drug Administration compliance status for our manufacturing facility in Boca Raton, Florida, which allowed us to s..." |
|
| 08/10/2018 |
8-K
| Quarterly results |
| 05/14/2018 |
8-K
| Quarterly results |
| 03/05/2018 |
8-K
| Quarterly results|
Docs:
|
"ADMA Biologics Reports Full Year 2017 Financial Results RAMSEY, N.J. and BOCA RATON, FL., – March 5, 2018 – ADMA Biologics, Inc. , a vertically integrated commercial biopharmaceutical and specialty immunoglobulin company that manufactures, markets and develops specialty plasma-derived biologics for the treatment of immmune deficiencies and prevention of certain infectious diseases, today announced its financial results for the year ended December 31, 2017. Financial Results for the Year Ended December 31, 2017 ADMA reported total revenues of $22.8 million for the year ended December 31, 2017, as compared to $10.7 million for the year ended December 31, 2016, representing an increase of $12.1 million, or approximately 113%. The increase in revenues was primarily due to the accretive nature ..." |
|
| 11/03/2017 |
8-K
| Quarterly results|
Docs:
|
"ADMA Biologics Provides Corporate Update and Reports Third Quarter 2017 Financial Results RAMSEY, N.J. – November 3, 2017 – ADMA Biologics, Inc. , a vertically integrated commercial biopharmaceutical and specialty immunoglobulin company that develops, manufactures and markets specialty plasma-based biologics for the treatment of Primary Immune Deficiency Disease and the prevention and treatment of certain infectious immunological diseases, today provided a corporate update, including recent progress with its manufacturing and quality systems, and announced its financial results for the fiscal quarter ended September 30, 2017. “Since completing the acquisition of certain assets of Biotest Pharmaceuticals Corporation’ s Therapy Business Unit , we are pleased to report we continue to make pro..." |
|
| 08/11/2017 |
8-K
| Quarterly results |
| 05/12/2017 |
8-K
| Quarterly results|
Docs:
|
"ADMA Biologics Provides Corporate Update and Reports First Quarter 2017 Financial Results RAMSEY, N.J. – May 12, 2017 – ADMA Biologics, Inc. , a late-stage biopharmaceutical company that develops, manufactures, and intends to commercialize specialty plasma-based biologics for the proposed treatment of immune deficiencies and prevention of certain infectious diseases, today announced its financial results for the quarter ended March 31, 2017, and provided a corporate update. “Throughout the first quarter of 2017, we continued to collaborate with Biotest Pharmaceuticals on our integration plan, and we look forward to completing and consummating our transformative transaction to acquire certain manufacturing and therapy-related business assets of Biotest Pharmaceuticals, expected to occur in ..." |
|
| 02/24/2017 |
8-K
| Form 8-K - Current report |
| 11/10/2016 |
8-K
| Form 8-K - Current report |
| 08/12/2016 |
8-K
| Quarterly results|
Docs:
|
"ADMA Biologics Reports Second Quarter 2016 Results RAMSEY, N.J. – August 12, 2016 – ADMA Biologics, Inc. , a late-stage biopharmaceutical company that develops, manufactures, and intends to commercialize specialty plasma-based biologics for the proposed treatment of immune deficiencies and prevention of certain infectious diseases, today announced its financial results for the quarter ended June 30, 2016. “We are working with our third-party vendors and the U.S. Food and Drug Administration to progress towards an approval of our Biologics License Application for our lead product candidate, RI-002, while also continuing to move forward with commercialization and pre-launch activities,” stated Adam Grossman, President and CEO of ADMA Biologics, Inc. “During the second quarter, we generated i..." |
|
| 03/23/2016 |
8-K
| Form 8-K - Current report |
| 11/12/2013 |
8-K
| Quarterly results |
| 08/12/2013 |
8-K
| Quarterly results |
| 03/06/2013 |
8-K
| Quarterly results |
| 11/13/2012 |
8-K
| Quarterly results|
Docs:
|
"ADMA BIOLOGICS, INC. AND SUBSIDIARY CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS For the Three Months Ended September 30, 2012 For the Three Months Ended September 30, 2011 For the Nine Months Ended September 30, 2012 For the Nine Months Ended September 30, 2011 REVENUES $ 360,338 $ - $ 594,834 $ - Cost of sales 144,691 - 288,761 - Gross profit 215,647 - 306,073 - OPERATING EXPENSES Research and development expenses 1,940,637 56,607 2,201,131 443,188 Loss on sale of research and development inventory" |
|
| 08/15/2012 |
8-K
| Quarterly results|
Docs:
|
"ADMA Biologics Reports 2012 Second Quarter Results HACKENSACK, N.J., August 14, 2012 - ADMA Biologics, Inc. , a late-stage biotechnology company focused on the development and commercialization of human plasma and plasma-derived therapeutics, today reported financial results for its second quarter ended June 30, 2012. Second Quarter and Subsequent Highlights · Executed multi-year agreement to supply normal source plasma collected from ADMA’s Norcross, Georgia plasma collection center to Biotest Pharmaceuticals Corporation. · Announced the addition of new board member and key executives: o Appointed plasma industry leader Lawrence Guiheen to Board of Directors o Named Brian Lenz as Chief Financial Officer o Named Dr. James Mond as Chief Medical and Scientific Officer “We made substantial pr...",
"ADMA Biologics Reports 2012 Second Quarter Results HACKENSACK, N.J., August 14, 2012 - ADMA Biologics, Inc. , a late-stage biotechnology company focused on the development and commercialization of human plasma and plasma-derived therapeutics, today reported financial results for its second quarter ended June 30, 2012. Second Quarter and Subsequent Highlights · Executed multi-year agreement to supply normal source plasma collected from ADMA’s Norcross, Georgia plasma collection center to Biotest Pharmaceuticals Corporation. · Announced the addition of new board member and key executives: o Appointed plasma industry leader Lawrence Guiheen to Board of Directors o Named Brian Lenz as Chief Financial Officer o Named Dr. James Mond as Chief Medical and Scientific Officer “We made substantial pr..." |
|
|
|